Fact Check: Did Lokesh Invest ₹6 Crore of Personal Funds in Punarvika Project?

In a remarkable display of personal commitment, Telugu Desam Party (TDP) leader Nara Lokesh has stepped forward to ensure life-saving treatment for one-year-old Punarvika, who suffers from a rare genetic disease. The intervention comes after a massive public fundraising campaign that had already collected approximately Rs 10 crore toward the child’s treatment.

According to official sources, Lokesh contributed Rs 6 crore from his personal funds to cover the remaining cost of Zolgensma, an injectable medication priced at Rs 16 crore that is required for Punarvika’s treatment. The high-cost gene therapy is one of the world’s most expensive medications and is not readily available in India, necessitating procurement from international sources.

The case had gained widespread attention across the Telugu community in recent weeks, with thousands of donors contributing to help the family reach their ambitious fundraising goal. However, despite the impressive community response, a significant funding gap remained, threatening to delay the time-sensitive treatment.

Lokesh was reportedly present with Punarvika’s family at Rainbow Hospital in Hyderabad during the process, demonstrating his personal involvement beyond just financial support. Sources indicate he played an instrumental role in navigating the logistical challenges of importing the specialized medication and ensuring its proper administration.

The high-profile intervention has not been without controversy. Some social media users have alleged that Lokesh was attempting to gain political mileage from the situation, with accusations that the funds came from the Andhra Pradesh government treasury rather than personal resources. These claims, however, have been refuted by an official fact-check that confirmed the contribution came from Lokesh’s personal finances.

Rare genetic disorders present unique challenges in India’s healthcare system, where treatments for such conditions often remain prohibitively expensive and frequently require specialized medications that must be imported. Zolgensma, developed by Novartis, is used to treat spinal muscular atrophy (SMA), a condition that progressively destroys nerve cells controlling muscle movement, potentially leading to paralysis and respiratory failure if left untreated.

The cost of rare disease treatments has become a significant point of discussion in India’s healthcare policy circles. While the National Policy for Rare Diseases provides some framework for addressing these conditions, many families still face insurmountable financial barriers when seeking treatment. Public fundraising campaigns, often conducted through crowdfunding platforms, have become a common but uncertain path for many such families.

Medical experts note that the timely administration of treatments like Zolgensma is crucial, as genetic disorders typically progress rapidly in young children, making early intervention essential for improving long-term outcomes.

This case highlights the growing intersection between political leadership and healthcare access in India, particularly for treatments that fall outside standard insurance coverage or government health programs. The situation underscores both the challenges families face in accessing high-cost specialized treatments and the potential role of individual philanthropy in addressing healthcare gaps.

For the family of Punarvika, the intervention represents hope in what had seemed like an impossible situation. While the full details of the child’s condition and prognosis remain private, the successful procurement of the medication marks a critical milestone in her treatment journey.

As this story continues to develop, it has sparked broader discussions about healthcare equity, the role of government in supporting rare disease treatments, and the responsibilities of leaders in addressing critical social needs within their communities.